Sort   by:  
 Page size 
UnknownRUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis.
Not available
S-EPMC11372367 | biostudies-literature
UnknownYTHDF1 targets the chemotherapy response by suppressing NOTCH1-induced stemness in colorectal cancer.
Not available
S-EPMC12719390 | biostudies-literature
UnknownPeptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.
Not available
S-EPMC11153135 | biostudies-literature
UnknownA Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Not available
S-EPMC7615905 | biostudies-literature
UnknownThe cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer.
Not available
S-EPMC9270407 | biostudies-literature
UnknownMETTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy.
Not available
S-EPMC10439254 | biostudies-literature
UnknownUltrafast laser-scanning time-stretch imaging at visible wavelengths.
Not available
S-EPMC6061895 | biostudies-literature
UnknownParvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients.
Not available
S-EPMC9439953 | biostudies-literature
UnknownDe Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
Not available
S-EPMC4746365 | biostudies-literature
UnknownSafety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Not available
S-EPMC12087306 | biostudies-literature
Sort   by:  
 Page size